ArticleCancer management and research2019
Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 44 citations in OpenAlex.
- Exploring the Role Of CD155 in Urothelial Carcinoma of the Urinary Bladder: An Immunohistochemical Study & Its Correlation With PD-L1.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.World journal of urology · 2025Article
- Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies.Exploration of targeted anti-tumor therapy · 2025Review
- Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer.Scientific reports · 2024Observational
- Article
- Article
- Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.Journal of clinical medicine · 2024Review
- Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target.Medical oncology (Northwood, London, England) · 2024Article
- How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?Molecular diagnosis & therapy · 2024Review
- The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers.Journal of cancer immunology · 2024Article
- Review
- Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data.Pathology oncology research : POR · 2023Article
- Programmed Death-ligand 1 (PD-L1) Expression in Bladder Cancer and its Correlation with Tumor Grade, Stage, and Outcome.Oman medical journal · 2022Article
- Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas.Journal of laboratory physicians · 2022Article
- Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.Clinical Medicine Insights. Oncology · 2022Review
- Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.Cancers · 2021Review
- Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.Cancer immunology, immunotherapy : CII · 2021Article
- Comparison of the Prognostic Value of Ki-67 and Programmed Cell Death Ligand-1 in Patients with Upper Tract Urothelial Carcinoma.Journal of clinical medicine · 2021Article
- Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.The oncologist · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.